S

Sarepta

Develops gene therapies for rare diseases

Research Associate 1

Full-Time
$62.8k - $78.5k/yr
Entry, Junior
Bachelor's
Columbus, OH, USA
In Person
Biology & BiotechTranslational Research & Bench Biology
No H1B Sponsorship

About the job

Requirements
  • A B.A. or B.S. degree in Biochemistry, Immunology, Cell Biology, Molecular Biology, Genetics, or a related field, with 0–3 years of relevant laboratory experience.
  • Ability to plan and conduct experiments while strictly following laboratory methods and standard operating procedures.
  • Proficient written and oral communication and presentation skills, with a documented ability to troubleshoot technical issues.
  • Strong problem-solving and data-analysis skills.
  • Highly organized, precise, and attentive to detail.
  • Ability to adhere to safety protocols and apply Good Laboratory Practices while advancing projects amid shifting priorities and timelines.
  • Experience with statistical and computer productivity software, including Word, Excel, Outlook, and Teams.
  • Recognized by former peers, colleagues, managers, or direct reports for attributes aligned with Sarepta Values.
Responsibilities
  • Assist with experiments under scientists’ direction and perform routine laboratory functions using assay formats such as nucleic acid and protein purification, Jess automated Western blot, ddPCR, RT-ddPCR, and ELISA.
  • Perform general laboratory maintenance and help maintain a clean, safe work environment in compliance with GCP/GLP guidelines.
  • Organize and maintain inventories of study-related samples for experiments.
  • Participate in implementing new technologies and laboratory techniques to improve the quality and robustness of sample analysis.
  • Train new employees on technical procedures, standard methods, practices, procedures, and equipment operations as assigned.
  • Troubleshoot routine technical challenges and contribute to their resolution.
  • Maintain compliant laboratory records and accurately document laboratory activities according to good documentation practices.
  • Perform other duties as assigned.

About the company

Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1980

Get referred to Sarepta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted AMONDYS 45 and VYONDYS 53 sNDAs; PDUFA lands February 28, 2027.
  • ENDEAVOR Cohort 8 enrollment finishes by year-end 2026, with Q1 2027 readouts.
  • Restructuring cut 36% of staff, targeting $400 million annual savings starting 2026.

What critics are saying

  • ELEVIDYS carries a boxed liver-injury warning; FDA may keep non-ambulatory patients excluded.
  • Q2 2026 ELEVIDYS revenue fell to $98.1 million after the 2025 safety reset.
  • If ENDEAVOR fails, Sarepta becomes a shrinking PMO company facing 2027 stagnation.

What makes Sarepta unique

  • Sarepta owns the deepest DMD franchise, spanning PMOs and ELEVIDYS commercialization.
  • Roche partnership supplies ex-U.S. manufacturing revenue and global Duchenne reach.
  • Michael Severino joined July 28, 2026, bringing AbbVie-style franchise execution discipline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Wellness Program

Growth & Insights and Company News

6 month growth

9%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Aug 27th, 2026
Sarepta rises 12% ahead of late-2026 muscular dystrophy trial data

Sarepta Therapeutics shares rose 12% on Thursday, heading for their best week since late March, as investors awaited clinical data updates. The company currently has four FDA-approved drugs for Duchenne muscular dystrophy. Investors are watching for mid-stage study data in two other muscle diseases, expected in the second half of 2026. Elevidys, Sarepta's Duchenne gene therapy, remains limited to patients who can walk following earlier safety concerns tied to liver failure. By year-end, the company expects to complete enrolment in a study of Elevidys with stronger immune-suppressing drugs in non-ambulatory patients. Early results are scheduled for the first quarter of 2027. Second-quarter product sales totalled $328.7 million, including $98.1 million from Elevidys. The company narrowed its 2026 product sales guidance to $1.2 billion–$1.3 billion.

Yahoo Finance
Jul 28th, 2026
Legend Biotech CEO abruptly resigns as Sarepta appoints ex-AbbVie president

Legend Biotech's CEO Ying Huang resigned abruptly on 24 July, with the company stating his departure was not due to any disagreement. Alan Bash, president of Legend's Carvykti Business Unit, will serve as interim CEO whilst a search for a permanent replacement is underway. Separately, Sarepta Therapeutics appointed Michael Severino as its new CEO following a five-month search. Severino, formerly president of AbbVie and CEO of Tessera Therapeutics, brings over 25 years of biopharma experience. He replaces Doug Ingram, who announced his retirement in February for personal reasons. The leadership changes come as Legend faces competition for its blockbuster CAR-T therapy Carvykti, whilst Sarepta recently implemented a 36% workforce reduction amid challenges with its DMD gene therapy Elevidys.

Associated Press
Jul 27th, 2026
Sarepta Therapeutics appoints AbbVie veteran Michael Severino as chief executive officer

Sarepta Therapeutics has appointed Michael Severino as chief executive officer, effective 28 July 2026. Severino, who will also join the board of directors, brings over 25 years of biopharmaceutical experience to the Cambridge-based precision genetic medicine company. Severino previously served as CEO of Tessera Therapeutics and held senior positions at AbbVie, where he was vice chairman and president responsible for research and development. At AbbVie, he oversaw pipeline expansion and contributed to more than a dozen approved therapies. He succeeds Doug Ingram, who is retiring after leading Sarepta through significant growth, including approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy. Ingram will serve in an advisory capacity until the end of 2026.

Yahoo Finance
Jul 14th, 2026
Sarepta's DMD therapies move closer to full FDA approval with sNDA acceptance

Sarepta Therapeutics announced the FDA has accepted supplemental New Drug Applications to convert accelerated approvals for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 to traditional approvals. The PDUFA action date is set for 28 February 2027. The applications are supported by the ESSENCE confirmatory study and real-world evidence from over 1,800 treated patients. This could strengthen the regulatory foundation of Sarepta's exon-skipping franchise. The development may help diversify Sarepta's regulatory position in DMD treatment, potentially offsetting concentration risk around its ELEVIDYS therapy. ELEVIDYS recently received an FDA boxed warning for acute liver injury in November 2025. Sarepta's narrative projects $1.4 billion revenue and $87.3 million earnings by 2029, requiring a 13.3% yearly revenue decline from current levels.

Yahoo Finance
May 14th, 2026
Sarepta Therapeutics' profit boosted by $52M unusual items amid 7.4% share dilution

Sarepta Therapeutics reported statutory profits that disappointed investors, with underlying concerns emerging from the earnings analysis. The company increased its share count by 7.4% over the past year, diluting per-share returns despite generating net income. The biotechnology firm was unprofitable three years ago and last year, making year-on-year growth comparisons difficult. Whilst the company achieved profit over the last 12 months, earnings per share would have been stronger without the share dilution. Additionally, Sarepta's profit received a significant boost from unusual items worth $52 million in the last 12 months. These one-off contributions may make statutory profit a poor indicator of underlying earnings power. The combination of share dilution and unusual items raises questions about the sustainability of the company's reported profitability.